News for Healthier Living

Osimertinib plus or minus Savolitinib in MET-EGFR NSCLC Trial

A groundbreaking phase 2 clinical trial has unveiled promising advancements in the treatment landscape for non-small cell lung cancer (NSCLC), specifically targeting patients harboring epidermal growth factor receptor (EGFR) mutations alongside MET gene aberrations. A research article (DOI:10.1038/s41467-025-67950-8) published recently in Nature Communications, the FLOWERS trial meticulously explored the efficacy of osimertinib -- a third-generation EGFR tyrosine kinase inhibitor (TKI) -- administered alone versus its combination with savolitinib, a potent MET inhibitor, as a frontline therapeutic strategy. The study's findings hold transformative potential for a substantial subset of NSCLC patients who traditionally face challenges with therapeutic resistance and disease progression.

February 11, 2026


February 11 2026

February 10 2026

February 9 2026

February 8 2026

February 7 2026

February 6 2026

February 5 2026

February 4 2026

February 3 2026

February 2 2026

February 1 2026

January 31 2026

January 30 2026

January 29 2026

January 28 2026